TeamWhat labs should I check before starting peptides and at follow-up?

A useful baseline has two parts: your health markers and the vial's proof. They answer different questions, and you want both before making a buying decision. A practical general baseline to discuss with a clinician often includes: 1. CBC for blood-cell counts. 2. CMP for kidney function, liver markers, electrolytes, glucose, and protein status. 3. A1C or fasting glucose, plus a fasting lipid panel. 4. Blood pressure, weight trend, and waist measurement. 5. Current medications, medical history, and the specific peptide category being considered. Then make the list compound-specific. For GLP-1 research, glucose and A1C trends matter, while kidney function and electrolytes deserve earlier review if persistent vomiting or dehydration occurs. For growth-hormone secretagogues, IGF-1 and glucose regulation are common discussion points. Thyroid, reproductive-hormone, or other specialized panels should be tied to the compound and the person's history, not added as a universal bundle. An 8-to-12-week review is a common practical checkpoint for trend-based markers, but it is not a rule. Medication changes, symptoms, rapid weight change, or an abnormal baseline can justify an earlier check. Use the same lab and similar testing conditions when possible so the trend is easier to interpret. Normal bloodwork does **not** prove a product is authentic. Before checkout, verify five separate items: exact lot match, named independent lab, identity by mass spectrometry, purity by HPLC or UPLC, and quantitative net content. Sterility and endotoxin evidence add another layer where relevant. See how PeptidePub evaluates testing at https://www.peptidepub.com/methodology, compare transparent sellers at https://www.peptidepub.com/vendors, and check effective pricing at https://www.peptidepub.com/prices.